Opportunity Pharma and OpenEye have joined forces in a groundbreaking collaboration to revolutionize drug discovery. Opportunity Pharma, a leading tech company in the AI field, will utilize OpenEye’s cutting-edge software to develop its artificial intelligence virtual expert for drug discovery investors. This partnership aims to provide curated comparisons of new drug investment opportunities, giving global life science investors and pharma companies the information they need to make informed decisions.
The drug discovery process is notorious for being costly, inefficient, and time-consuming. However, Opportunity Pharma aims to change that with the help of OpenEye. By utilizing OpenEye’s Orion platform and its range of applications and toolkits, Opportunity Pharma will make portfolio and project investment decisions more objective, rigorous, and transparent. The goal is to reduce drug program failures and stimulate investment in novel drug discovery, ultimately leading to more high-quality medicines.
OpenEye, known for its work in computational molecular design, is excited to support Opportunity Pharma in their quest to provide clarity for drug discovery investors. By using OpenEye software, pharmaceutical and biotechnology companies can connect with investment resources that are looking to improve human health. The collaboration between Opportunity Pharma and OpenEye is a testament to their shared vision for innovation and excitement in the field.
To develop the virtual expert, Opportunity Pharma will collaborate with partners specializing in IT, AI, and machine learning technology. They will create a database of investable opportunities for various disease areas and drug targets, using curated scientific, development, and commercial criteria. This comprehensive approach will ensure that decision science methodology software can be built to prioritize projects and select the most promising drug programs.
The virtual expert, which is set to launch in 2024, will revolutionize the drug discovery landscape. By providing users with relevant big data and insights, Opportunity Pharma and OpenEye aim to empower investors and researchers to make informed decisions about drug discovery. With this exciting partnership, the future of drug discovery looks brighter than ever.
What are your thoughts on this groundbreaking collaboration between Opportunity Pharma and OpenEye? Do you think it will revolutionize drug discovery? Leave your comments below and let us know what you think!
IntelliPrompt curated this article: Read the full story at the original source by clicking here